President gets broad power to cut medical tariffs; Congress can only block deals

What it does

This bill authorizes the President to negotiate and enter into trade agreements with countries that meet certain criteria (rule of law, IP protection, regulatory standards, commitment to open medical trade during emergencies) to reduce or eliminate tariffs and trade barriers on medical goods. Congress retains a 30–90 day review window to disapprove agreements by joint resolution. The goal is to diversify U.S. medical supply sources and strengthen resilience against future pandemics.

Why we flagged it

The bill's core mechanism is a delegation of tariff-setting power to the President, constrained by congressional disapproval rights. It is not a direct subsidy, immunity grant, or deregulation—it is a procedural framework for negotiating medical-goods trade agreements. The stated purpose (supply-chain resilience) is genuine, but the operative effect is a significant expansion of presidential discretion in trade policy.

What the text implies

• The bill does not require Congress to affirmatively approve agreements—only to disapprove them. This inverts the normal legislative burden: a trade deal takes effect unless Congress acts, making inaction equivalent to consent. A disapproval resolution requires both chambers and the President's signature (or veto override), a high bar.
• The 'trusted trade partner' criteria in Section 5(b) are advisory, not binding. The President 'shall take into account' them but is not required to find that a partner meets all criteria before negotiating. This creates discretion to negotiate with countries that fail to meet stated standards.
• Section 5(c)(10) exempts parties to the agreement from 'trade-restrictive measures imposed with respect to medical goods during a public health emergency.' This could prevent the U.S. from imposing export controls or tariffs on medical goods from a partner even if that partner restricts exports to the U.S. during a crisis.
• The bill does not define 'medical goods' narrowly. Section 4(4) includes 'any input for' a medical device or drug, potentially covering raw materials, chemicals, and manufacturing equipment—a very broad category that could encompass non-medical industrial goods.
• Tariff elimination may lower prices for consumers but could also reduce domestic manufacturing investment and capacity, undermining the stated goal of supply-chain resilience. The bill does not require domestic production targets or capacity maintenance.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens may benefit from lower medical-device and drug prices via reduced tariffs and supply-chain diversification, and from pandemic-preparedness improvements. However, the bill grants broad executive authority with minimal substantive constraints on partner selection, and the congressional review mechanism is weak (disapproval requires affirmative joint resolution, not approval). Domestic manufacturers of medical goods may face increased import competition, potentially reducing U.S. productio

Who stands to gain

• pharmaceutical companies (lower tariffs on imports)
• medical-device manufacturers (tariff reduction, regulatory harmonization)
• importers and distributors of medical goods
• foreign manufacturers in partner countries (tariff-free access to U.S. market)

Named in the bill

President of the United States, United States Trade Representative, Congress (House Committee on Ways and Means, Senate Committee on Finance), Department of Health and Human Services, International Trade Commission, World Trade Organization, Agreement on Government Procurement, Federal Food, Drug, and Cosmetic Act

Where it stands

21 cosponsors: 14 Democrats, 7 Republicans.

• Mar 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 18, 2025 — Referred to House Committee on Rules and House Committee on Ways and Means · Congress.gov: “Referred to the Committee on Ways and Means, and in addition to the Committee on Rules, for a period to be…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

13 lobbying clients named this bill on 21 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $59,937,000 in lobbying spend. A filing names 14 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 94% of bills with at least one filing.

Nicole Malliotakis, the sponsor, reported $1,140,250 in PAC receipts in the 2026 cycle. $3,500 of that came from 2 PACs tied to these lobbying clients.

• Chamber of Commerce of the U.S.A. — $54,660,000 on 3 filings
• UPS (united Parcel Service) — $1,500,000 on 1 filing
• America's Essential Hospitals — $1,080,000 on 2 filings
• Trinity Health — $720,000 on 3 filings
• Cencora, Inc. — $510,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.